ArticleJournal of medical case reports2026
Exceptional and typical biomarker responses to AminoTriComplex in metastatic prostate cancer: a case series.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastatic prostate cancer (mPCa) remains a major cause of mortality in men. AminoTriComplex, a multicomponent phytochemical-melatonin formulation, targets inflammation, extracellular matrix remodeling, androgen receptor signaling, and circadian dysregulation. CASE PRESENTATION: We present a case series of eight Caucasian/White male patients (aged 58-73 years; median 66) with histologically confirmed metastatic castration-resistant prostate cancer (mCRPC) from the active treatment arm of a double-blind, placebo-controlled trial. Patients received AminoTriComplex as adjuvant therapy alongside standard of care. Seven "typical" responders were associated with deep prostate-specific antigen (PSA) declines (79-89%), matrix metalloproteinase-9 (MMP-9) reductions (45-55%), interleukin-6 (IL-6) decreases (55-62%), and universal AR-V7 conversion to negative. One "exceptional" responder (a 62-year-old Caucasian/White man) was associated with a 96% PSA decline, normalization of inflammatory and protease biomarkers, complete AR-V7 clearance, restoration of circadian rhythm, and > 30% radiographic regression per RECIST 1.1 criteria for nodal disease. MECHANISTIC SUBSTUDY: Tumor biopsies and blood demonstrated strengthened MT1 melatonin receptor expression, synchronous downregulation of Survivin, and elevation of Cystatin C, aligning with clinical biomarker shifts.
conclusionsAminoTriComplex was associated with consistent biomarker modulation and occasional exceptional responses; these hypothesis-generating observations warrant validation in larger controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.